



A33865 (090495.0233)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Takashima et al.

Serial No. : 09/808,555

Examiner : Gerald R. Ewoldt

Filed : June 6, 2000

Group Art Unit : 1644

For : IN SITU LANGERHANS CELL VACCINE

Customer No.: 21003

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450.

November 6, 2003

Date of Deposit

Rochelle K. Seide, Ph.D.

Attorney Name

Rochelle K. Seide  
Signature

32,300

Patent Reg. No.

November 6, 2003

Date of Signature

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents listed on the attached Form PTO 1449 and respectfully request that the listed documents be considered by the Examiner and made of record in the above-captioned application.

11/13/2003 SZENDIE1 00000097 09808555

01 FC:1806

180. OP

NY02:464323.1

## PATENT


Copies of all of the documents listed on the Form PTO-1449 are enclosed. The listed documents were cited in International Search Report in the corresponding PCT Application No. PCT/US02/07645. A copy of the International Search Report is enclosed.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a final action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution, and is accompanied by the fee set forth in 37 C.F.R. §1.17(p). However, if any additional fee is due, the Commissioner is authorized to charge any such fee or credit any overpayment, to our Deposit Account No. 02-4377. A duplicate copy of this sheet is enclosed for that purpose.

Respectfully submitted,

BAKER BOTTS L.L.P.

By:



Rochelle K. Seide, Ph.D.

Patent Office Reg. No. 32,300

30 Rockefeller Plaza

44th Floor

New York, NY 10012-4498

Attorney for Applicants

212-408-2500

Form PTO-1449 U.S. Department of Commerce  
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.  
A33865 - 090495.0233

Serial No.  
09/808,555

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

(Use several sheets if necessary)

Applicants  
Takashima et al.

Filing Date  
June 6, 2000

Group Art Unit  
1644

**U.S. PATENT DOCUMENTS**

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate
	6 1 2 1 0 2 0	09/19/00	Selby et al.	435	69.3	
	6 0 4 8 5 2 7	04/11/00	Granoff et al.	424	150.1	

**FOREIGN PATENT DOCUMENT**

Document No.	Date	Country	Class	SubClass	Translator Yes No

**OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)**

	Kim et al. (1998) "CD8 Positive T Cells Influence Antigen-Specific Immune Responses through the Expression of Chemokines", J. Clin. Invest. 102: pps. 1112-1124.
	Ohnishi et al. (1993) "Successful in Vivo Generation of Canine Lymphokine-Activated Killer Cells by Continuous Recombinant Interleukin-2 Infusion through the Splenic Artery", Cancer Biotherapy 8: pps. 213-222.
	Smith et al. (1987) "A phase I study of rDNA alpha-2b interferon as a 6-week continuous intravenous infusion", Cancer Chemother. Pharmacol. 20: pps. 327-331.

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NY02:464330.1